ethyl 2-(3-(2,6-dimethylbenzyloxy)-4-methylphenyl)acetate | 1200397-46-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: ethyl 2-(3-(2,6-dimethylbenzyloxy)-4-methylphenyl)acetate
• 英文别名: Ethyl 2-(3-(2,6-dimethybenzyloxy)-4-methylphenyl)acetate；ethyl 2-[3-[(2,6-dimethylphenyl)methoxy]-4-methylphenyl]acetate
• CAS: 1200397-46-1
• 化学式: C₂₀H₂₄O₃
• 分子量: 312.409
• InChiKey: UQJWBCJLGFUEEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-(3-(2,6-dimethylbenzyloxy)-4-methylphenyl)acetate 在 水 、 sodium hydroxide 、 盐酸 作用下， 以 乙醇 、 氯仿 、 水 为溶剂， 反应 3.0h， 生成 2-(3-(2,6-dimethylbenzyloxy)-4-methylphenyl)acetic acid
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHOD FOR REDUCING URIC ACID
  [FR] COMPOSÉS ET PROCÉDÉ DE RÉDUCTION DE L'ACIDE URIQUE

  摘要：

  公开号：

  WO2009151695A4
• 作为产物：
  描述：

  3-甲氧基-4-甲基苯乙酸 在 三溴化硼 、 potassium carbonate 、 对甲苯磺酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 31.0h， 生成 ethyl 2-(3-(2,6-dimethylbenzyloxy)-4-methylphenyl)acetate
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHOD FOR REDUCING URIC ACID
  [FR] COMPOSÉS ET PROCÉDÉ DE RÉDUCTION DE L'ACIDE URIQUE

  摘要：

  公开号：

  WO2009151695A4

文献信息

• COMPOUNDS AND METHOD FOR REDUCING URIC ACID
  申请人：O'NEIL Rita M.

  公开号：US20130259850A1

  公开（公告）日：2013-10-03

  Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I or a pharmaceutically acceptable salt thereof. In Formula I m is 0, 1, 2, 3 or 4; n is 0 or 1; m+n is not more than 4; t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. R 6 is hydrogen, methyl or ethyl and R 12 is hydrogen or methyl, or R 6 is hydroxy and R 12 is hydrogen, or R 6 is O and R 12 is absent, or R 6 and R 12 together are —CH 2 CH 2 —. R 7 is hydrogen or alkyl having from 1 to 3 carbon atoms. One of R 8 and R 9 is alkyl having from 1 to 3 carbon atoms, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms. R 10 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms or alkoxy having from 1 to 3 carbon atoms. X is C(O) and r is 0 and t is 0; or X is NH(R 11 ) wherein R 11 is hydrogen or alkyl having from 1 to 3 carbon atoms. A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from halo, hydroxy, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, and perfluoromethoxy; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of Formula I by a ring carbon; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently monosubstituted by methyl or ethyl. The uric acid-lowering effects of the Compounds of Formula I are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, and cognitive impairment.

  在哺乳动物主体中，通过给予化合物I的一个衍生物或其药学上可接受的盐，可以降低尿酸并增加尿酸的排泄。在公式I中，m为0、1、2、3或4；n为0或1；m+n不超过4；t为0或1；q为0或1；r为0、1或2。R6为氢、甲基或乙基，R12为氢或甲基，或者R6为羟基且R12为氢，或者R6为O且R12不存在，或者R6和R12共同为—CH2CH2—。R7为氢或有1至3个碳原子的烷基。R8和R9中的一个为有1至3个碳原子的烷基，另一个为氢或有1至3个碳原子的烷基。R10为氢、卤素、有1至3个碳原子的烷基或有1至3个碳原子的烷氧基。X为C（O），r为0且t为0；或X为NH（R11），其中R11为氢或有1至3个碳原子的烷基。A为苯基，未取代或取代为1或2个从卤素、羟基、甲基、乙基、全氟甲基、甲氧基、乙氧基和全氟甲氧基中选择的基团；或为有1或2个从N、S和O中选择的环杂原子的5或6成员杂环芳基环，且该杂环芳基环通过一个环碳原子与公式I的其余部分共价结合；或为有3至6个环碳原子的环烷基，其中环烷基未取代或其中一或两个环碳原子独立地被甲基或乙基单取代。公式I的降低尿酸作用可用于治疗或预防多种疾病，包括痛风、高尿酸血症、尿酸水平升高但不符合惯常诊断高尿酸血症的水平、肾功能障碍、肾结石、心血管疾病、发生心血管疾病的风险、肿瘤溶解综合征和认知障碍。
• Compounds and method for reducing uric acid
  申请人：WELLSTAT THERAPEUTICS CORPORATION

  公开号：US09115072B2

  公开（公告）日：2015-08-25

  Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I or a pharmaceutically acceptable salt thereof. In Formula I m is 0, 1, 2, 3 or 4; n is 0 or 1; m+n is not more than 4; t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. R6 is hydrogen, methyl or ethyl and R12 is hydrogen or methyl, or R6 is hydroxy and R12 is hydrogen, or R6 is O and R12 is absent, or R6 and R12 together are —CH2CH2—. R7 is hydrogen or alkyl having from 1 to 3 carbon atoms. One of R8 and R9 is alkyl having from 1 to 3 carbon atoms, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms. R10 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms or alkoxy having from 1 to 3 carbon atoms. X is C(O) and r is 0 and t is 0; or X is NH(R11) wherein R11 is hydrogen or alkyl having from 1 to 3 carbon atoms. A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from halo, hydroxy, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, and perfluoromethoxy; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of Formula I by a ring carbon; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently monosubstituted by methyl or ethyl. The uric acid-lowering effects of the Compounds of Formula I are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, and cognitive impairment.

  在哺乳动物主体中，通过给予公式I或其药学上可接受的盐，可以降低尿酸并增加尿酸的排泄。在公式I中，m为0、1、2、3或4；n为0或1；m+n不超过4；t为0或1；q为0或1；r为0、1或2。R6为氢、甲基或乙基，R12为氢或甲基，或R6为羟基且R12为氢，或R6为O且R12不存在，或R6和R12一起为-CH2CH2-。R7为氢或具有1至3个碳原子的烷基。R8和R9中的一个为具有1至3个碳原子的烷基，另一个为氢或具有1至3个碳原子的烷基。R10为氢、卤素、具有1至3个碳原子的烷基或具有1至3个碳原子的烷氧基。X为C（O），r为0且t为0；或X为NH（R11），其中R11为氢或具有1至3个碳原子的烷基。A为苯基，未取代或被1或2个选自卤素、羟基、甲基、乙基、全氟甲基、甲氧基、乙氧基和全氟甲氧基的基团取代；或具有1或2个选自N、S和O的杂环芳香环的5或6个成员，且杂环芳香环通过一个环碳原子与公式I的余下部分共价结合；或具有从3到6个环碳原子的环烷基，其中环烷基未取代或一个或两个环碳原子分别被甲基或乙基单取代。公式I化合物的降低尿酸作用可用于治疗或预防多种疾病，包括痛风、高尿酸血症、尿酸水平升高但不符合通常诊断高尿酸血症的水平、肾功能障碍、肾结石、心血管疾病、患心血管疾病的风险、肿瘤溶解综合征和认知障碍。
• EP2268141A1
  申请人：——

  公开号：EP2268141A1

  公开（公告）日：2011-01-05
• COMPOUND AND METHOD FOR REDUCING URIC ACID
  申请人：Wellstat Therapeutics Corporation

  公开号：EP2268141B1

  公开（公告）日：2019-05-08
• US9115072B2
  申请人：——

  公开号：US9115072B2

  公开（公告）日：2015-08-25